|
TARSL2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
8.67159999362599E-09 |
| Normal-vs-Stage3 |
9.99200722162641E-16 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
1.884450E-01 |
| Stage1-vs-Stage3 |
5.399600E-01 |
| Stage1-vs-Stage4 |
4.655600E-02 |
| Stage2-vs-Stage3 |
1.504030E-01 |
| Stage2-vs-Stage4 |
1.587790E-02 |
| Stage3-vs-Stage4 |
2.084200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
5.70129999999391E-05 |
| Normal-vs-Asian |
1.70075065142328E-12 |
| Caucasian-vs-AfricanAmerican |
1.044170E-01 |
| Caucasian-vs-Asian |
4.736800E-01 |
| AfricanAmerican-vs-Asian |
2.142800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.99520433297585E-15 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
2.259400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
2.31137331496711E-12 |
| Normal-vs-Age(81-100Yrs) |
3.68330000000139E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.072200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.803200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.972200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.198000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.419000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.550000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.16289999996244E-06 |
| Classical-VS-Follicular |
4.280800E-01 |
| Classical-VS-Other |
8.861000E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
3.6427000000061E-05 |
| Tall-VS-Other |
1.352570E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
8.886000E-01 |
| Follicular-VS-Normal |
5.42569988937203E-10 |
| Other-VS-Normal |
6.157300E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.11022302462516E-16 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
1.258160E-02 |
|
|
